시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 특발성 두개내압 항진증 치료 시장 보고서(2025년)
Idiopathic Intracranial Hypertension Treatment Global Market Report 2025
상품코드 : 1751024
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,324,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,141,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 11,958,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

특발성 두개내압 항진증 치료 시장 규모는 향후 수년간 강력한 성장이 전망될 예정입니다. 도구의 가용성 확대, 맞춤형 의료에 대한 수요 증가로 인한 것입니다. 예측 기간의 주요 동향으로는 AI 구동 진단 도구 사용, 표적 치료 개발, 비침습적 이미지 기술 진보, 새로운 체중 관리 약물 도입, 맞춤형 션트 장치 생성 등이 있습니다.

비만의 유병률 증가는 향후 몇 년간의 특발성 두개내압 항진증 치료 시장의 확대를 촉진할 것으로 예측됩니다. 비만의 증가는 좌식 라이프스타일 증가나 칼로리가 높은 가공식품의 섭취가 주요 원인이 되고 있습니다. 비만은 뇌척수액의 과잉 생산을 촉진하고 흡수를 방해하여 두개내압 증가에 기여하며, 이는 특발성 두개내압 항진증 발생에 중요한 역할을 합니다. 예를 들어, 영국 정부 부문인 건강 개선 격차 대책실의 2024년의 보고서에 의하면, 2022년부터 2023년 사이에, 영국의 18세 이상의 성인의 64.0%가 과체중 또는 비만으로 분류되었습니다. 이 숫자는 2021년에서 2022년까지보고된 63.8%와 거의 같습니다.

특발성 두개내압 항진증 치료 시장의 주요 기업은 두개내압 관리와 관련 증상의 완화를 목표로 한 혁신적인 치료법의 개발에 주력하고 있습니다. 이러한 치료법은 첨단 약물 전달 시스템과 표적 치료 접근법을 통해 환자의 결과를 개선하여 전반적인 치료와 삶의 질을 향상시키는 것을 목표로 합니다. 2022년 11월, 호주에 본사를 둔 바이오 제약 회사 인벡스 테라퓨틱스는 뉴질랜드 의약품 및 의료기기 안전청(MEDSAFE)으로부터 특발성 두개내압 항진증 치료를 위한 프레젠딘(지속 방출 엑세나타이드)의 임상 3상 IIH EVOLVE 임상시험 개시 승인을 받았습니다. 이번 승인과 뉴질랜드 건강 및 장애 윤리 위원회의 승인을 통해 인벡스는 최대 40개의 글로벌 임상 현장에서 240명의 신규 IIH 환자를 대상으로 임상시험을 진행할 수 있게 되었으며, 이는 이 신경 질환에 대한 치료 결과를 개선하는 것을 목표로 합니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 금리, 인플레이션, 지정학, 무역전쟁과 관세, 코로나 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

SHW
영문 목차

영문목차

Idiopathic intracranial hypertension (IIH) treatment involves medical and surgical approaches aimed at lowering intracranial pressure and preventing complications such as vision loss. These treatments may include lifestyle modifications, such as weight loss, medications such as acetazolamide to reduce fluid buildup, and surgical interventions, including shunt placement or optic nerve sheath fenestration in more severe cases.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The main treatment types for idiopathic intracranial hypertension include medications, surgeries, and therapies. Medications are used to reduce cerebrospinal fluid production, relieve symptoms such as headaches and visual disturbances, and manage underlying conditions. These medications are typically administered orally or intrathecally. Diagnostic methods for IIH include neuroimaging, lumbar puncture, and visual field tests, and treatments are generally provided in hospitals, specialized clinics, or ambulatory surgical centers.

The idiopathic intracranial hypertension treatment market research report is one of a series of new reports from The Business Research Company that provides idiopathic intracranial hypertension treatment market statistics, including the idiopathic intracranial hypertension treatment industry's global market size, regional shares, competitors with a idiopathic intracranial hypertension treatment market share, detailed idiopathic intracranial hypertension treatment market segments, market trends and opportunities, and any further data you may need to thrive in the idiopathic intracranial hypertension treatment industry. This idiopathic intracranial hypertension treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The idiopathic intracranial hypertension treatment market size has grown strongly in recent years. It will grow from$1.38 billion in 2024 to $1.48 billion in 2025 at a compound annual growth rate (CAGR) of 6.9%. The growth during the historic period can be attributed to several factors, including the rising prevalence of obesity, increased healthcare spending, a growing emphasis on minimally invasive surgical techniques, the increasing prevalence of comorbid conditions, and a higher demand for advanced ophthalmologic diagnostic tools.

The idiopathic intracranial hypertension treatment market size is expected to see strong growth in the next few years. It will grow to$1.91 billion in 2029 at a compound annual growth rate (CAGR) of 6.6%. The growth during the forecast period can be attributed to the growing adoption of digital health solutions, the rise in lifestyle-related disorders, increased use of telemedicine, greater availability of advanced diagnostic tools, and a growing demand for personalized medicine. Key trends in the forecast period include the use of AI-driven diagnostic tools, the development of targeted therapies, advancements in non-invasive imaging techniques, the introduction of new weight management medications, and the creation of customizable shunt devices.

The growing prevalence of obesity is expected to drive the expansion of the idiopathic intracranial hypertension (IIH) treatment market in the coming years. Obesity is a medical condition characterized by excessive body fat, which can harm overall health. The rise in obesity is largely attributed to increasingly sedentary lifestyles and the consumption of calorie-dense processed foods. Obesity contributes to increased intracranial pressure by promoting the overproduction of cerebrospinal fluid and impairing its absorption, which plays a key role in the development of idiopathic intracranial hypertension. For instance, according to a 2024 report from the Office for Health Improvement and Disparities, a UK government department, 64.0% of adults aged 18 and older in England were classified as overweight or obese between 2022 and 2023. This figure is nearly the same as the 63.8% reported for the 2021 to 2022 period. Therefore, the rising obesity rates are significantly driving the growth of the idiopathic intracranial hypertension treatment market.

Leading companies in the idiopathic intracranial hypertension treatment market are focusing on developing innovative therapies aimed at managing intracranial pressure and alleviating associated symptoms. These therapies aim to improve patient outcomes through advanced drug delivery systems and targeted treatment approaches, thereby enhancing overall care and quality of life. For example, in November 2022, Invex Therapeutics, an Australia-based biopharmaceutical company, received approval from the New Zealand Medicines and Medical Devices Safety Authority (MEDSAFE) to begin the Phase III IIH EVOLVE clinical trial for Presendin (sustained-release exenatide) in the treatment of idiopathic intracranial hypertension (IIH). This approval, along with clearance from the New Zealand Health and Disability Ethics Committee, allows Invex to conduct the trial with 240 newly diagnosed IIH patients at up to 40 global clinical sites, aiming to improve treatment outcomes for this neurological condition.

In March 2024, Bristol Myers Squibb, a US-based pharmaceutical company, acquired Karuna Therapeutics Inc. for $12 billion. This acquisition enhances Bristol Myers Squibb's neuroscience portfolio by adding KarXT, a novel antipsychotic with a unique mechanism of action and a promising efficacy and safety profile. The acquisition aligns with Bristol Myers Squibb's long-term growth strategy and strengthens its ability to address unmet needs in neurodegenerative conditions. Karuna Therapeutics Inc. is a US-based biopharmaceutical company that focuses on developing therapies for neurological disorders.

Major players in the idiopathic intracranial hypertension treatment market are Siemens AG, Medtronic plc, Mayo Clinic, Becton Dickinson and Company, Philips Healthcare, GE HealthCare Technologies Inc., Teva Pharmaceuticals, Boston Scientific Corporation, Henry schein, Sun Pharmaceutical Industries, Zydus LifeSciences, Topcon Corporation, Natus Medical Incorporated, Canon Medical Systems Corporation, Carl Zeiss Meditec AG, Optopol Technology, Strides Pharma, NIDEK Co., Haag-Streit AG, Invex Therapeutics, and Metrovision.

North America was the largest region in the idiopathic intracranial hypertension treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in idiopathic intracranial hypertension treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the idiopathic intracranial hypertension treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The idiopathic intracranial hypertension treatment market consists of revenues earned by entities by providing services such as diagnostic imaging services, nutritional counseling, optic nerve sheath fenestration procedures, ophthalmologic evaluations, and visual field monitoring. The market value includes the value of related goods sold by the service provider or included within the service offering. The idiopathic intracranial hypertension treatment market also includes sales of shunt systems, surgical instruments, intracranial pressure monitoring devices, and optical coherence tomography (OCT). Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Idiopathic Intracranial Hypertension Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on idiopathic intracranial hypertension treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for idiopathic intracranial hypertension treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The idiopathic intracranial hypertension treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Idiopathic Intracranial Hypertension Treatment Market Characteristics

3. Idiopathic Intracranial Hypertension Treatment Market Trends And Strategies

4. Idiopathic Intracranial Hypertension Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Idiopathic Intracranial Hypertension Treatment Growth Analysis And Strategic Analysis Framework

6. Idiopathic Intracranial Hypertension Treatment Market Segmentation

7. Idiopathic Intracranial Hypertension Treatment Market Regional And Country Analysis

8. Asia-Pacific Idiopathic Intracranial Hypertension Treatment Market

9. China Idiopathic Intracranial Hypertension Treatment Market

10. India Idiopathic Intracranial Hypertension Treatment Market

11. Japan Idiopathic Intracranial Hypertension Treatment Market

12. Australia Idiopathic Intracranial Hypertension Treatment Market

13. Indonesia Idiopathic Intracranial Hypertension Treatment Market

14. South Korea Idiopathic Intracranial Hypertension Treatment Market

15. Western Europe Idiopathic Intracranial Hypertension Treatment Market

16. UK Idiopathic Intracranial Hypertension Treatment Market

17. Germany Idiopathic Intracranial Hypertension Treatment Market

18. France Idiopathic Intracranial Hypertension Treatment Market

19. Italy Idiopathic Intracranial Hypertension Treatment Market

20. Spain Idiopathic Intracranial Hypertension Treatment Market

21. Eastern Europe Idiopathic Intracranial Hypertension Treatment Market

22. Russia Idiopathic Intracranial Hypertension Treatment Market

23. North America Idiopathic Intracranial Hypertension Treatment Market

24. USA Idiopathic Intracranial Hypertension Treatment Market

25. Canada Idiopathic Intracranial Hypertension Treatment Market

26. South America Idiopathic Intracranial Hypertension Treatment Market

27. Brazil Idiopathic Intracranial Hypertension Treatment Market

28. Middle East Idiopathic Intracranial Hypertension Treatment Market

29. Africa Idiopathic Intracranial Hypertension Treatment Market

30. Idiopathic Intracranial Hypertension Treatment Market Competitive Landscape And Company Profiles

31. Idiopathic Intracranial Hypertension Treatment Market Other Major And Innovative Companies

32. Global Idiopathic Intracranial Hypertension Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Idiopathic Intracranial Hypertension Treatment Market

34. Recent Developments In The Idiopathic Intracranial Hypertension Treatment Market

35. Idiopathic Intracranial Hypertension Treatment Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기